Searched for
CDMO SERVICES
Gland Pharma appoints Dr Reddy’s senior executive Deepak Sapra as CEOGland Pharma has appointed Deepak Sapra as its new chief executive officer, with his tenure set to begin on November 16, 2026, subject to h...- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsWhat is volatility? There is, of course, a mathematical definition. Then there is the human definition, which is how investors feel it. In ...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- Gland Pharma inks strategic CDMO deal with global pharma firm, eyes $90-100 million annual revenueGland Pharma has signed a strategic Manufacturing and Supply Agreement with a leading global pharmaceutical company for technology transfer...
- These mid-cap stocks with ‘Strong Buy’ & ‘Buy’ recos can rally over 25%, according to analystsA word of caution for all those who have exposure to mid cap stocks or are planning to increase it. Just keep one thing in mind: If there i...
- ET Health Conclave 2026: Healthcare leaders reimagine the future of medicine through innovation, prevention and technologyThe ET Health Conclave 2026 celebrated healthcare professionals and institutions. Leaders shared insights on healthcare infrastructure and ...
- BDR Pharmaceuticals eyes controlling stake in Acme FormulationPAG acquired a controlling stake in Acme Formulation for $145 million (?1,054 crore) through its PAG Asia III buyout fund in 2021. Founder ...
- Index returns likely to be slightly above long-term averages over next 2 years: Mirae Asset CIO Neelesh Surana on market outlook, fund strategiesMirae Asset Investment Managers (India)’s equity funds have experienced a period of underperformance—the first major blip since inception i...
- Shantha Biologics to make injectable drug cartridges for Novo NordiskShantha Biologics has secured a significant contract with Danish pharmaceutical giant Novo Nordisk to manufacture cartridges for injectable...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...
- The hidden reason global capital is looking beyond India for future growthForeign investors are reallocating capital away from India towards markets like Taiwan and South Korea that offer stronger exposure to AI a...
- Brokerages stay bullish on Laurus Labs as CDMO momentum and margins improveLaurus Labs' stock has surged 30% on robust FY26 results, fueled by a booming contract manufacturing business and improved product mix. The...
- Banking, capital goods and midcaps seen driving market's next rally: Ashish ChaturmohtaIndian equities are poised for fresh highs, driven by strong earnings and sector-specific momentum, particularly in financials and manufact...
- The 30% smallcap tilt: How Abakkus Flexi Cap Fund is positioning for the next rallyAbakkus Mutual Fund is strategically allocating 30% to smallcaps within its Flexi Cap Fund, identifying mispriced opportunities despite str...
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...
- Granules India shares in focus on acquiring Swiss firm for Rs 192 crGranules India has acquired Swiss CDMO company Senn Chemicals AG for Rs 192 crore, expanding its peptide therapeutics market presence. The ...
- Granules acquires Swiss firm for Rs 192 cr; forays into CDMO spaceGranules India has acquired Swiss CDMO firm Senn Chemicals AG for CHF 20 million, expanding into the peptide therapeutics segment. The acqu...
- Suven, Cohance aim to double combined business revenue to Rs 6,000 cr by FY29Suven Pharmaceuticals and Cohance Lifesciences plan to merge and aim to double their revenue to Rs 6,000 crore by FY29 through organic and ...
- Innova Captab share price jumps 20% after tepid listing. What should investors do?The lackluster debut performance fell way short of expectations, which highlights the potential risks associated with the highly competitiv...
- Innova Captab shares list at just 2% premium over issue priceThe IPO of Innova Captab received tremendous response from investors with 55.26 times subscription at close. The issue received bids of 50,...
Load More
